Environmental cues determine the fate of astrocytes after spinal cord injury

Fatima M. Nathan, Shuxin Li
Shriners Hospitals Pediatric Research Center, Department of Anatomy and Cell Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA

How to cite this article: Nathan FM, Li S (2017) Environmental cues determine the fate of astrocytes after spinal cord injury. Neural Regen Res 12(12):1964-1970.

Funding: This work was supported by research grants to SL from NIH (1R01NS079432 and 1R01EY024575) and Shriners Research Foundation (SHC-86300-PHI, SHC-86200-PHI-16 and SHC-85100).

Abstract

Reactive astrogliosis occurs after central nervous system (CNS) injuries whereby resident astrocytes form rapid responses along a graded continuum. Following CNS lesions, naïve astrocytes are converted into reactive astrocytes and eventually into scar-forming astrocytes that block axon regeneration and neural repair. It has been known for decades that scarring development and its related extracellular matrix molecules interfere with regeneration of injured axons after CNS injury, but the cellular and molecular mechanisms for controlling astrocyte scar formation and maintenance are not well known. Recent use of various genetic tools has made tremendous progress in better understanding genesis of reactive astrogliosis. Especially, the latest experiments demonstrate environment-dependent plasticity of reactive astrogliosis because reactive astrocytes isolated from injured spinal cord form scarring astrocytes when transplanted into injured spinal cord, but revert in retrograde to naïve astrocytes when transplanted into naïve spinal cord. The interactions between upregulated type I collagen and its receptor integrin β1 and the N-cadherin-mediated cell adhesion appear to play major roles for local astrogliosis around the lesion. This review centers on the environment-dependent plasticity of reactive astrogliosis after spinal cord injury and its potential as a therapeutic target.

Key Words: astrogliosis; astrocyte fate; scar formation; spinal cord injury; axon regeneration; environment cue; collagen I; integrin β1

Introduction

Astrocytes are the most abundant non-neuronal, highly differentiated cells that span the entire central nervous system (CNS) (Tower and Young, 1973). They have many important physiological functions in the CNS, including maintaining extracellular ion, transmitter and fluid balance, regulating blood flow, influencing synaptic plasticity and contributing to many other essential functions (Nedergaard et al., 2003; Seifert et al., 2006; Pellerin et al., 2007). Astrocytes are classified into different subtypes principally based on their locations and functions. Fibrous astrocytes populate the white matter and encompass of dense glial filaments with cylindrical processes. Protoplasmic astrocytes reside in the gray matter with fewer glial filaments and irregular processes in comparison (Vaughn and Pease, 1967). In contrast, radial astroglia are the Bergmann glia in cerebellum and Müller cell in retina (Molofsky et al., 2012).

Astrocytosis is a pathological process involved in excessive generation of astrocytes in response to CNS damages following trauma and in different neurological diseases. Because of destruction to the brain-blood barrier, leakage of serum and plasma, increased inflammatory reactions (such as activation of microglia and generation of various cytokines), and enhanced activation of transforming growth factor β (TGF-β) and SMAD2 signaling pathways, CNS injuries usually induce proliferation and migration of reactive astrocytes (RAs) at and around injury site and thus an increase in their number. Reactive astrocytes often exhibit characteristic structural changes, including marked hypertrophy and substantial overlap of astrocytic domains (Karimi-Abdolrezaee and Billakanti, 2012). Reactive astrocytes highly upregulate a large number of molecules, including different intermediate filaments, nestin, signaling proteins and many other molecules (Ridet et al., 1997; Sofroniew, 2009). In addition to the featured reactive astrocytes around lesion, injury site consists of NG2-expressing glia (including oligodendrocyte precursor cells), meningeal and vascular derived fibroblasts, pericytes, ependymal cells and phagocytic macrophages (Cregg et al., 2014).

Astrogliosis may result in both beneficial and maladaptive effects mainly depending on its time course and dynamic features (Sofroniew, 2014). Reactive astrogliosis occurs after various CNS lesions, including spinal cord injury (SCI). The primary benefits of glial scars include separation of inflammation of injury area from the intact tissues and minimize the extent of secondary damage after CNS injury. Several studies demonstrated that elimination of astrogliosis early after CNS injury resulted in greater lesion area and worse functional outcomes (Bush et al., 1999; Sofroniew, 2009; Burda and Sofroniew, 2014; Anderson et al., 2016). In response to injury, local naïve astrocytes (NAs) display sequential changes in phenotypes, initially as RAs and then as scar-forming astrocytes (SAs) (Bushong et al., 2002; Wilhelmsson et al., 2006). In contrast to individual, finely branched processes of NAs, which occupy non-overlapping domains, RAs are distinguished by hypertrophy of cell body and overlap of processes. At acute stage after CNS injury, RAs have various beneficial effects because the overlapped processes of RAs and incorporation of newly proliferated cells around the lesion separate damaged areas from healthy tissues and limit the spread of inflammatory cells (Faulkner et al., 2004; Herrmann et al., 2008). At subacute phase (4–14 days after SCI in mouse model), migrated RAs to the lesion epicenter isolate inflamma-
tory cells and repair the lesion area for functional enhancement (Okada et al., 2006). However, at chronic phase (>14 days after SCI in mice), RAs gradually convert into SAs and form scarring tissues, the major barrier for CNS axon regeneration (Silver and Miller, 2004; Pekny and Nilsson, 2005; Karimi-Abdolrezae and Billakanti, 2012; Ohtake and Li, 2015).

With various genetic approaches, a group recently reported the determining role of environmental conditions for reactive astrocytes (Hara et al., 2017). Isolated RAs from injured spinal cord reverted to NAs when transplanted into non-injured spinal cord, while formed SAs when transplanted into injured spinal cord. Moreover, pharmacologically blocking interactions between type I collagen and its integrin receptor prevented astrocytic scar formation and improved axonal regrowth and functional recovery. Astrogliosis has long been considered a major barrier to axon regeneration, although RAs are able to support neurite extension under certain conditions and corticospinal axons could sprout in adult injured spinal cord during reactive gliosis (Li and Raisman, 1995; Sivron and Schwartz, 1995). The recent advance in better understanding molecular control of scar genesis may lead to development of new approaches for overcoming scar-based regeneration failure.

**Gene Expression Profile and Marker Proteins in Various Subtypes of Astrocytes after SCI**

It is extremely important to identify the gene expression profile and molecular markers for various subtypes of astroglia, including NAs, RAs and SAs (Ricker et al., 1997). Glial fibrillary acidic protein (GFAP) has been recognized as an astrocyte specific intermediate filament (IF) protein necessary for maintaining CNS function and blood-brain barrier integrity (Liedtke et al., 1996; Kakinuma et al., 1998). A great number of studies have employed GFAP as a primary marker for astrocytic scars by detection of its immunoreactivity. Before altering expression of various other proteins, reactive glia upregulate the IF proteins GFAP, vimentin and nestin (Deddlestone and Mucke, 1993; Hernandez et al., 2002), which contribute to IF network formation (Barrett et al., 1981). Mice deficient in GFAP showed reduced IF formation and altered neuronal activities (Pekny et al., 1995; McCall et al., 1996). Astrogliosis appeared normal after CNS injury in GFAP−/− mice; EGF and NGF upregulate the expression of both significantly impaired scar formation frequently accompanied by bleeding around the lesion (Pekny et al., 1999).

Several groups studied the gene expression profiling of purified astrocyte populations and made progress in revealing potential new markers (Doyle et al., 2008; Fu et al., 2009; Rowitch and Kriegstein, 2010), including identification of Aldh1L1 and fibroblast growth factor (FGF) receptor 3 as the markers (Pringle et al., 2003; Cahoy et al., 2008). However, Okada’s group further characterized the gene expression profile in different subtypes of astrocytes and defined the potential use of some genes as respective markers (Hara et al., 2017). It is crucial to distinguish different subtypes of astrocytes (NAs, RAs and SAs). As a conventional method, histological analysis has been long been used to differentiate them. Because both RAs and SAs express various hallmark proteins (such as glial fibrillary acidic protein (GFAP), nestin, β-catenin, N-cadherin and sex determining region Y-box 9 (SOX9)) and their expression levels are highly dynamic with time, it is difficult to differentiate them primarily based on histological analysis of characteristic expression (Cregg et al., 2014). Many groups also employed fluorescence activated cell sorting and translating ribosomal affinity purification to analyze cell types after separating solid organ tissues into individual cells (Doyle et al., 2008; Kumamaru et al., 2012). In contrast, by using laser microdissection combined with immunohistochemistry, Hara et al. (2017) selectively isolated NAs, RAs and SAs from contused mouse spinal cord at different stages and recognized clear distinctions among three astrocyte subtypes based on the expression profile of marker genes (Figure 1). Because of the graded continuum of gene expression and structural alterations during astrogliosis, it seems advantageous to combine marker gene profiling and morphological definitions for identifying various astrocyte phenotypes (Yokota et al., 2015; Hara et al., 2017).

Several genes are appropriate as the RA markers, including nestin (a type VI IF protein), Ctnnb1 (a gene encoding β-catenin), Plaur (encoding urokinase receptor, also known as urokinase-type plasminogen activator receptor, uPAR), MMP2 (encoding matrix metalloproteinase 2), MMP13 (encoding matrix metalloproteinase 13) and Axin2 (also known as axin-like protein) (Hara et al., 2017). Plaur binds both precursor and mature forms of urokinase plasminogen activator and activates the receptor-bound pro-enzyme by plasmin, including the matrix metalloproteinases, thus promoting cell-surface plasminogen activation, plasmin formation and degradation of the extracellular matrix (ECM) molecules. RAs upregulate GFAP, nestin, vimentin and Ctnnb1 comparing to NAs, but only four of these genes, only Ctnnb1 and nestin are suitable gene markers for RAs because SAs also upregulate GFAP and vimentin. Comparing to both NAs and SAs, RAs also uniquely upregulate Plaur, MMP2 and MMP13 and Axin2 (a negative feedback regulator for β-catenin). Therefore, the six genes of nestin, Ctnnb1, Plaur, MMP2, MMP13 and Axin2 are selectively expressed by RAs and may serve as the RA specific markers (Fig. 1A).

In addition to serving as the RA marker, β-catenin related genes appear important to mediate RA migration in the lesioned spinal cord (Hara et al., 2017). The highly expressed β-catenin in cytosol could bind T cell factory lymphoid enhancer factor (Tcf/Lef) and form the protein complex, which increases expression of uPAR (Lengyel et al., 1996). Upregulation of uPAR then accelerates cell surface plasmin formation, results in extracellular matrix proteolysis by activating MMPs (Ellis et al., 1991), and thus regulates migration of cells, including RAs. RA migration appears essential for promoting tissue repair and functional recovery after SCI (Okada et al., 2006).

Comparing to NAs and RAs, SAs selectively upregulate Sox9, N-cadherin (also known as cadherin 11), TIMP-1 (encoding matrix metalloproteinase 2), MMP13 (encoding matrix metalloproteinase 13) and chondroitin sulfate proteoglycan (CSPG) related genes (Yxl1, Chst11, Csgalnact1, Acan and Pcan). SOX9 is expressed as a HMG box transcription factor by neural stem cells in embryonic spinal cord (Molofsky et al., 2012) and its deletion in conditional knockout mice by nestin-Cre predisposed to extend neurogenesis period and to delay gliogenesis onset in developing spinal cord (Stoll et al., 2003). SOX9 upregulates CSPGs in astrocyte cultures and conditional SOX9 deletion promotes axon regrowth by reducing CSPG levels (Gris et al., 2007). CSPGs encompass a diverse group of extracellular matrix proteins (i.e., neurocan, aggrecan, brevican, versican, phosphocan, and NG2) and experience posttranslational alterations with complex glycosaminoglycan chains differing in sulfation patterns and length (Margolis and Margolis, 1994). CSPGs could block axon elongation during development and after CNS injury (Brittis et al., 1992; Wu et al., 1998). SOX9 deficiency downregulated certain chondroitin sulfate synthesizing enzymes, such as Xylt1/2 and C4st1 (McKillop et al., 2013; Takeuchi et al., 2013). SOX9 deletion also increased immunoreactivity puncta for synaptophysin several weeks after SCI and enhanced synaptic reconnections, resulting in improved recovery (McKillop et al., 2013). Therefore, upregulation of SOX9 by SAs probably correlates with axon growth failure mediated by CSPG overexpression after SCI.
reactive astrocytes develop with time after injury. A great number of studies demonstrate the potent suppression of axon regrowth by denovo scar sourced inhibitors (McKeon et al., 1991; Davies et al., 1997; Ohtake and Li, 2015). Adult sensory neurons robustly regenerated their axons after micro-transplantation into intact white matter tracts by minimizing scar genesis, but failed to regrow when approaching lesioned region with scar tissues (Silver and Miller, 2004). Digestion of the glycosaminoglycan side chains by chondroitinase ABC (ChABC) improves axon regeneration and sprouting after various CNS injuries (Bradbury et al., 2002; Allain et al., 2011). Creation of a permissive environment around the lesion by combined peripheral nerve autographs, acidic fibrinogen, and chondroitinase ABC (ChABC) enhanced recovery of urination and respiratory functions after SCI (Allain et al., 2011; DePaul et al., 2015).

Reactive astrogliosis is reversible under certain conditions and local environment plays a major role in determining the fate of astrocytes in situ. The molecular mechanisms for astrocytic scar formation are not well known in spite of increased number of studies in this field. To further elucidate the molecular control of astrogliosis, Hara et al. (2017) transplanted isolated green fluorescent protein (GFP)-positive NAs from primary cultures into uninjured or contusively-injured spinal cord in mice and characterized the morphological and gene expression changes of NAs at 7 and 14 days after transplantation. Surprisingly, NAs exhibited the properties and marker gene expression of RAs at 7 days and of SAs at 14 days after transplantation into the injured spinal cord. In contrast, the grafted NAs into uninjured spinal cord remained unchanged in morphology and gene expression profile. Moreover, isolated GFP-positive RAs showed properties of SAs by upregulating SA marker genes 7 days after transplantation into injured spinal cord, but reverted back to NAs with suppressed SA gene expressions 7 days after transplantation into uninjured spinal cord.

Uregulation of type 1 collagen (Col 1) and N-cadherin around the lesion plays important roles in astrogliosis. Because activated astrocytes upregulated various cell surface molecules, including ECM molecules and cell adhesion molecules (Aubert et al., 1995; Merrill and Benveniste, 1996), Hara et al. (2017) further determined the expression levels of these genes around lesion by Gene Ontology term analysis and detected enhanced ECM genes 14 days after SCI, especially Col 1 related genes (Col1a1 and Col1a2). Immunostaining indicated co-localization of Col 1 with SA-forming astrocytic scars, but not with non-converting RAs even 14 days after injury. Consistently, cultured RAs showed close adhesion on Col 1 coated plates and increased GFAP expression (characteristic of SAs), but RAs retracted their processes and reduced GFAP expression when cultured on non-coated plates (Hara et al., 2017). Thus, expression of Col 1 in RAs appears to correlate with conversion of RAs to SAs and astrocytic scar tissues following SCI. Because astrocytic scars upregulated N-cadherin, which was distributed following astrocytic structures (Vázquez-Chona and Geisert, 1999; Takeichi, 2007; Tran et al., 2008), N-cadherin also appears to play a significant role of in inducing RA transformation into SAs (Hara et al., 2017).

Lesion Environment Determines Astrocytic Fate and Scar Formation after SCI

Both extracellular and intrinsic factors are important in controlling axon growth failure after CNS injury in adult mammals (Silver and Miller, 2004; Liu et al., 2011). For the former, an inhibitory environment due to scar formation at lesion site is critical for regenerative failure (Fawcett, 2006). However, the overall roles of reactive astrogliosis are complicated and reactive astrocytes may have numerous beneficial functions. Scar tissues have repairing roles after CNS damage by generating many ECM components with growth-promoting properties, such as fibronectin and laminin (Silver and Miller, 2004). In addition to acting as an accommodating bridging support for regeneration, RAs express polysialylated neuronal cell adhesion molecule and facilitate axon growth by interacting with other positive molecules, such as L1 (Aubert et al., 1995; Rutishauser and Landmesser, 1996). Astrocytes and other cell types around lesion have been reported to promote axon regrowth after SCI (Kawaja and Gage, 1991; Fawcett and Asher, 1999).

Migration of a great number of astrocytes into and around the lesion areas and formation of scar tissues create both physical and chemical barriers of axon regeneration. Importantly, upregulation of suppressing substances, particularly CSPGs, strongly blocks neural repair and axon regeneration. The inhibitory properties of reactive astrocytes develop with time after injury. A great number of studies demonstrate the potent suppression of axon regrowth by denovo scar sourced inhibitors (McKeon et al., 1991; Davies et al., 1997; Ohtake and Li, 2015). Adult sensory neurons robustly regenerated their axons after micro-transplantation into intact white matter tracts by minimizing scar genesis, but failed to regrow when approaching lesioned region with scar tissues (Silver and Miller, 2004). Digestion of the glycosaminoglycan side chains by chondroitinase ABC (ChABC) improves axon regeneration and sprouting after various CNS injuries (Bradbury et al., 2002; Allain et al., 2011). Creation of a permissive environment around the lesion by combined peripheral nerve autographs, acidic fibrinogen, and chondroitinase ABC (ChABC) enhanced recovery of urination and respiratory functions after SCI (Allain et al., 2011; DePaul et al., 2015).

Reactive astrogliosis is reversible under certain conditions and local environment plays a major role in determining the fate of astrocytes in situ. The molecular mechanisms for astrocytic scar formation are not well known in spite of increased number of studies in this field. To further elucidate the molecular control of astrogliosis, Hara et al. (2017) transplanted isolated green fluorescent protein (GFP)-positive NAs from primary cultures into uninjured or contusively-injured spinal cord in mice and characterized the morphological and gene expression changes of NAs at 7 and 14 days after transplantation. Surprisingly, NAs exhibited the properties and marker gene expression of RAs at 7 days and of SAs at 14 days after transplantation into the injured spinal cord. In contrast, the grafted NAs into uninjured spinal cord remained unchanged in morphology and gene expression profile. Moreover, isolated GFP-positive RAs showed properties of SAs by upregulating SA marker genes 7 days after transplantation into injured spinal cord, but reverted back to NAs with suppressed SA gene expressions 7 days after transplantation into uninjured spinal cord.

Uregulation of type 1 collagen (Col 1) and N-cadherin around the lesion plays important roles in astrogliosis. Because activated astrocytes upregulated various cell surface molecules, including ECM molecules and cell adhesion molecules (Aubert et al., 1995; Merrill and Benveniste, 1996), Hara et al. (2017) further determined the expression levels of these genes around lesion by Gene Ontology term analysis and detected enhanced ECM genes 14 days after SCI, especially Col 1 related genes (Col1a1 and Col1a2). Immunostaining indicated co-localization of Col 1 with SA-forming astrocytic scars, but not with non-converting RAs even 14 days after injury. Consistently, cultured RAs showed close adhesion on Col 1 coated plates and increased GFAP expression (characteristic of SAs), but RAs retracted their processes and reduced GFAP expression when cultured on non-coated plates (Hara et al., 2017). Thus, expression of Col 1 in RAs appears to correlate with conversion of RAs to SAs and astrocytic scar tissues following SCI. Because astrocytic scars upregulated N-cadherin, which was distributed following astrocytic structures (Vázquez-Chona and Geisert, 1999; Takeichi, 2007; Tran et al., 2008), N-cadherin also appears to play a significant role of in inducing RA transformation into SAs (Hara et al., 2017).

Essential Roles of Type I Collagen-Integrin Interactions and N-Cadherin-Mediated Adhesion in Astrocytic Scar Formation

Recent experiments with time-dependent RNA-seq analysis supports that upregulation of ECM Col 1 is necessary for astrocytic scar formation (Hara et al., 2017). Following SCI, pericytes and fibroblasts generated Col 1 in the lesion epicenter (Göriz et al., 2011; Gregg et al., 2014; DePaul et al., 2015). Pericytes...
attract other types of cells to the lesion area two weeks after SCI when the scar is compartmentalized and the lesion center is enclosed initially by an astrocytic layer derived from ependymal cells. Then, another astrocytic layer resulting from self-duplication of resident astrocytes further surrounds the lesion area (Barnabé-Heider et al., 2010; Göritz et al., 2011). Thus, the collagen-generating pericytes are essential in enclosing spinal cord lesions (Göritz et al., 2011). Similarly, pericytes in fibrotic kidney and dermal scars could differentiate into collagen-forming cells and also contributed to scarring formation in these organs (Sundberg et al., 1996; Humphreys et al., 2010).

As the transmembrane receptors, integrins are expressed in multiple cells in the CNS, including pericytes, neurons, glia and endothelial cells, and have multiple essential functions (del Zoppo and Milner, 2006). Integrins play important roles in regulating inflammation, growth cone motility, astrocyte proliferation, and axon guidance and regrowth after injury (Lemons and Condic, 2008). Integrins control collagen synthesis during cell degeneration (Gardner et al., 1999). Upregulation of integrins increases neuronal adhesion and outgrowth and reduces aggrecan-mediated inhibition of cell adhesion. Moreover, integrins maintain growth cone motility of neurons over a broad range of ligand concentrations and allow axons to invade different tissues during development and regeneration (Condic and Le tourneau, 1997; Condic et al., 1999).

A number of studies indicate the involvement of integrins in astrocytic pathological changes. Astrocytes express various integrins, including a1β1, a2β1, a10β1 and a11β1 (Previtali et al., 1997; Yonezawa et al., 2010), and regulate cell functions by interacting with Col 1 (Hynes, 2002). Particularly, integrins contribute to induction of NAs to Ras (Avalos et al., 2002, 2004). After brain injury in mice, mRNA levels for integrins a1 and β1 and for GFP were increased simultaneously in the endfeet of astrocytes encompassing blood vessels (Yonezawa et al., 2010). Pilocarpine-induced seizures increased integrin α1 and β1 immunoreactivity in RAs of rat brain (Fasen et al., 2003). In contrast, oxygen-glucose deprivation reduced α1 expressions in astrocytes of mice (Milner et al., 2008). Integrins promote cancer cell motility and invasion with frequently altered levels by directly interacting with ECM components (Desgrosellier and Cheresh, 2010). Accordingly, altered expression of ECM molecules and integrins, concurs with tumor cell functions by promoting cell adhesion and metastasis (Barnabé-Heider et al., 2010; Göritz et al., 2011). This complexity indicates the vast range of interactions between reactive astrocytes and surrounding cells at acute, subacute and chronic phases. Accordingly, astrogliosis has both beneficial and detrimental functions largely depending on its dynamic structures and chemical components at different stages. Numerous studies have demonstrated the hindering effects of reactive scar tissues around lesion and attempted to promote axon regeneration by preventing scar formation with many molecular and cellular methods. However, Anderson et al. (2016) recently further studied function of reactive astrocytes after SCI using diverse cell ablation models and reported positive effects of reactive astrocytes on neural repair. By using transgenic mouse models and diminished production of reactive astrocytes at chronic stage, Anderson et al. (2016) reported attenuated axon regeneration of descending and ascending tracts across the lesion in adult mice with SCI, indicating that the astrocytic scars around injury promoted axon regeneration, instead of blocking regrowth of injured axonal tracts.

Because a number of studies support that SAs are highly suppressive for axon elongation after CNS injury (Silver and Miller, 2004; Karimi-Abdolrezaee and Billakanti, 2012; Cregg et al., 2014), intervening transformation of RAs to SAs and minimizing scar formation can help injured axons grow and potentially improve functional recovery. Administering anti-β1 antibody 9–13 days after SCI significantly attenuated SA formation, downregulated both N-cadherin and GFAP, and reduced cell adhesion and scar formation around the lesion (Hara et al., 2017). Similarly, treatment with a N-cadherin antibody also decreased astrocytic scar formation. Importantly, anti-β1 Ab treatment increased the numbers of descending serotonin and tyrosine hydroxylase fibers in the caudal spinal cord and also appeared to improve behavioral recovery in mice with SCI. Thus, blocking Col 1-integrin β1 signaling pathway and/or N-cadherin-mediated cell adhesion may suppress scar formation

The recent study by Hara et al. (2017) further supports the timing-dependent and functional relevance of Col1, integrin β1 and N-cadherin during astrogliosis after SCI. Cell adhesion of RAs concurred with regulation of N-cadherin and GFAP proteins. Treatment with an anti-β1 antibody blocked expression levels of N-cadherin and GFAP with scattered appearances. Accordingly, treatment with a N-cadherin-neutralizing antibody suppressed transformation of RAs into SAs. Moreover, the timing-dependent N-cadherin expression correlated well with observed cellular hypertrophy and process elongation of RAs and SAs (Hara et al., 2017). Because astrocytes formed N-cadherin-mediated adhesions and SAs exhibited elevated levels of N-cadherin (Vázquez-Chona and Geisert, 1999; Hara et al., 2017), the enhanced RA contacts mediated by N-cadherin appear important for astrogliosis by inducing RAs into SAs regulated through interactions between Col 1 and its receptor integrin β1.

Therapeutic Potential for CNS Regeneration by Reducing Astrogliosis

Because of complicated and sequential nature of astrogliosis, it is important to define detailed features of astrogliosis after CNS injury and to design effective therapies that target specific molecular and cellular changes at a given stage (Silver and Miller, 2004; Cafferty et al., 2008; Sharma et al., 2012). Various ligands/receptors and signaling pathways contribute to astrogliosis after CNS injury, including collagens, integrins, cadherins, JNK/c-Jun, STAT, Smads, MAPK, SOCs, and RhoA (Okada et al., 2006; Gadea et al., 2008; Herrmann et al., 2008; Sofroniew and Vinters, 2010; Kang and Hebert, 2011). This complexity indicates the vast range of interactions between reactive astrocytes and surrounding cells at acute, subacute and chronic phases. Accordingly, astrogliosis has both beneficial and detrimental functions largely depending on its dynamic structures and chemical components at different stages. Numerous studies have demonstrated the hindering effects of reactive scar tissues around lesion and attempted to promote axon regeneration by preventing scar formation with many molecular and cellular methods. However, Anderson et al. (2016) recently further studied function of reactive astrocytes after SCI using diverse cell ablation models and reported positive effects of reactive astrocytes on neural repair. By using transgenic mouse models and diminished production of reactive astrocytes at chronic stage, Anderson et al. (2016) reported attenuated axon regeneration of descending and ascending tracts across the lesion in adult mice with SCI, indicating that the astrocytic scars around injury promoted axon regeneration, instead of blocking regrowth of injured axonal tracts.

Because a number of studies support that SAs are highly suppressive for axon elongation after CNS injury (Silver and Miller, 2004; Karimi-Abdolrezaee and Billakanti, 2012; Cregg et al., 2014), intervening transformation of RAs to SAs and minimizing scar formation can help injured axons grow and potentially improve functional recovery. Administering anti-β1 antibody 9–13 days after SCI significantly attenuated SA formation, downregulated both N-cadherin and GFAP, and reduced cell adhesion and scar formation around the lesion (Hara et al., 2017). Similarly, treatment with a N-cadherin antibody also decreased astrocytic scar formation. Importantly, anti-β1 Ab treatment increased the numbers of descending serotonin and tyrosine hydroxylase fibers in the caudal spinal cord and also appeared to improve behavioral recovery in mice with SCI. Thus, blocking Col 1-integrin β1 signaling pathway and/or N-cadherin-mediated cell adhesion may suppress scar formation.
and become an effective approach for providing axon regeneration after CNS injury.

Because JNK (c-Jun N-terminal kinase) signaling pathway appears to link Col 1-integrin interactions to N-cadherin-mediated cell adhesion in astrocytes (Shintani et al., 2006a, b; Ha et al., 2017), targeting JNK and N-cadherin pathways may also reduce scar formation and enhance regenerated axons to cross the lesion area after CSN injury. Stimulation of Col 1-integrin axis activates JNK signaling by increasing the levels of phosphorylated-JNK and N-cadherin in astrocytes after CNS injury (Vázquez-Chona and Geisert, 1999). Spinal nerve ligation injury increased expression of c-Jun, the substrate of JNK, and levels of phosphorylated c-Jun in GFAP cells of the ipsilateral spinal cord, indicating that peripheral axon injury activates JNK signal in spinal cord astrocytes (Raivich et al., 2004; Raivich and Makwana, 2007). In addition, JNK activation due to activating Col 1-integrin axis induced N-cadherin-dependent cell adhesion in other types of cells, including epithelial and cancer cells (Shintani et al., 2006a, b).

TGF-β/Smad signaling pathways contribute to scar formation and also appear the therapeutic targets (Lindholm et al., 1992; Gomes et al., 2005). TGF-β signaling regulates proliferation, differentiation and survival of many cells by activating Smad dependent or independent pathways. TGF-β acts as a major upstream activator of CSPG upregulation during astrogliosis. Although TGF-β treatment reduced lesion area after acute SCI by decreasing macrophage infiltration into the injury site, but TGF-β eventually stimulated CSPG production by astrocytes and fibroblasts and scarring tissue formation, inhibiting regeneration at subacute and chronic stages (Smith and Strunz, 2005; Schachtrup et al., 2010; Susarla et al., 2011). Blocking TGF-β/Smad2 signaling by TGF-β antibody and its receptor inhibitor, or inhibiting its upstream activator fibrogin attenuated CSPGs generation and glial scar formation (Gris et al., 2007; Schachtrup et al., 2010). As the downstream signal of TGF-β, Smad2 appears to mediate scar gliosis by activating intrinsic transcriptional program in astrocytes. Inhibiting kinesin-dependent Smad2 translocation with taxol, a microtubule stabilizing agent, diminished scarring tissues around the lesion (Hellal et al., 2011).

As a transcription factor and a downstream signal for multiple cytokines and growth factors, signal transducer and activator of transcription 3 (STAT3) mediates scar formation after CNS injury and may be a molecular target for CNS repair (Fitch and Silver, 1997; Silver and Miller, 2004; Okada et al., 2006; Herrmann et al., 2008). Deletion of STAT3 in conditional knockout mice with nestin-Cre caused failed astrocyte migration to the lesion site and exacerbated infiltration of inflammatory cells around the lesion (Hellal et al., 2011). STAT3 signaling is an essential part of astrogliosis at subacute and chronic stages after lesion (Smith and Strunz, 2005; Schachtrup et al., 2010; Susarla et al., 2011). Blocking TGF-β/Smad2 signaling by TGF-β antibody and its receptor inhibitor, or inhibiting its upstream activator fibrogin attenuated CSPGs generation and glial scar formation (Gris et al., 2007; Schachtrup et al., 2010). As the downstream signal of TGF-β, Smad2 appears to mediate scar gliosis by activating intrinsic transcriptional program in astrocytes. Inhibiting kinesin-dependent Smad2 translocation with taxol, a microtubule stabilizing agent, diminished scarring tissues around the lesion (Hellal et al., 2011).

As a transcription factor and a downstream signal for multiple cytokines and growth factors, signal transducer and activator of transcription 3 (STAT3) mediates scar formation after CNS injury and may be a molecular target for CNS repair (Fitch and Silver, 1997; Silver and Miller, 2004; Okada et al., 2006; Herrmann et al., 2008). Deletion of STAT3 in conditional knockout mice with nestin-Cre caused failed astrocyte migration to the lesion site and exacerbated infiltration of inflammatory cells around the lesion after SCI. Conditional deletion of STAT3 from astrocytes downregulated GFAP expression and prevented astrocytic hypertrophy and astroglial scar formation after SCI (Okada et al., 2006; Herrmann et al., 2008). Also, conditional deletion of STAT3 from GFAP+ cells significantly blocked astrocyte development. Several other signaling molecules also contribute to scarogenesis and may become the therapeutic targets. SOX9 is essential for CSPGs expression after CNS injury probably by regulating xylosyltransferase I and II during CSPG biosynthesis in astrocytes (Karimi-Abdolrezae and Billakanti, 2012). As the downstream signaling molecules of integrins, focal adhesion kinase and Ras/Rho GTPases may also contribute to astrogliosis and CNS regeneration failure after CNS injury. Several studies have supported the crucial role of small GTPases in regulating neurite extension, axon regeneration and guidance (Hall and Nobes, 2000; Raftopoulou and Hall, 2004; Fu et al., 2007). In addition, the integrins-GTPases pathway may function as bi-directional signals by mediating upstream or downstream molecules during scar genesis (Schwartz and Shattil, 2000; Lemons and Condic, 2008).

Prospective
Recent studies have made tremendous progress in astrogliosis after CNS injuries, including identifying specific marker genes for different astrocyte subtypes, illustrating environment-dependent plasticity of reactive astrogliosis, and developing effective strategies for neural repair by targeting scar related mechanisms. Over the past decades, scientists have employed various approaches to minimize negative outcomes of astrogliosis (Pekny and Nilsson, 2005; Herrmann et al., 2008), to block scar-sourced inhibitory molecules genetically and pharmaceutically (Bradbury et al., 2002; Fisher et al., 2011; Lang et al., 2015) to reduce upregulation of axon growth inhibitors, especially CSPGs (Grimpe and Silver, 2004; Rolls et al., 2008), to bridge lesion area with various cell/biomaterial transplants. For development of novel and highly effective therapies to repair injured CNS, it is important to further characterize diverse activities of different astrocyte subtypes, signaling control of scar formation, and the scar associated molecules, including markers, receptors and expression factors. Because astrogliosis is highly complicated and dynamic with the injury stages, it may have damaging, beneficial and mixed effects on neural recovery largely depending on the injury types, degrees, phases, location and other essential factors. It thus is important to develop specific strategies to target environment-dependent individual cellular and molecular mechanisms at a given stage, including the major signaling pathways of astrogliosis at upstream or downstream level. It is also interesting to formulate effective therapies by minimizing damaging outcomes and maximizing protective effects of reactive glial tissues by targeting individual molecules and cell types.

Author contributions: Both FMN and SL contributed to writing the paper and making the figure.

Conflicts of interest: None declared.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms.

References
Allain WJ, Horn KP, Hu H, Dick TE, Silver J (2011) Functional regeneration of respiratory pathways after spinal cord injury. Nature 475:196-200.
Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming TJ, Sofroniew MV (2016) Astrocyte scar formation aids central nervous system axon regeneration. Nature 532:195-200.
Aubert I, Ridet JL, Gage FH (1995) Regeneration in the adult mammalian CNS: guided by development. Curr Opin Neurobiol 5:625-635.
Avalos AM, Labra CV, Quest AF, Leyton L (2002) Signaling triggered by Thy-1 interaction with beta 3 integrin on astrocytes is an essential step towards unraveling neuronal Thy-1 function. Biol Res 35:231-238.
Avalos AM, Arthur WT, Schneider P, Quest AF, Burridge K, Leyton L (2004) Aggregation of integrins and RhoA activation are required for Thy-1-induced morphological changes in astrocytes. J Biol Chem 279:39193-39145.
Barnabé-Heider F, Gótzia C, Sabelstöm H, Takebayashi H, Pifréger FW, Meletis K, Frisen J (2010) Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell 7:470-482.
Barrett CP, Guth L, Donati EJ, Krickorian JG (1981) Astroglial reaction in the gray matter lumbar segments after midlumbar transection of the adult rat spinal cord. Exp Neurol 73:365-377.
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416:636-640.
Brittis PA, Cannin DR, Silver J (1992) Chondroitin sulphate as a regulator of neuronal patterning in the retina. Science 253:733-736.

1968
Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, Tessier-Lavigne M, Kidd T (1999) Silt proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 96:795-806.

Burda J, Sofroniev MV (2014) Reactive gliosis and the multacellular response to CNS damage and disease. Neuron 81:229-248.

Bush TG, Poreanchandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke L, Johnson MH, Sofroniev MV (1999) Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23:297-308.

Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplastic astrocytes in CA1 surround excitatory inputs, separate anatomical domains. J Neurosci 22:183-192.

Cafferty WB, McGee AW, Strittmatter SM (2008) Axonal growth therapeutics: regeneration or sprouting or plasticity? Trends Neurosci 31:215-220.

Calho YD, Emery JD, Kaulash A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A transcriptiondatabase for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28:264-278.

Carninci P, Hayashizaki Y (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118.

Condic ML, Letourneau PC (1997) Ligand-induced changes in integrin expression regulate neuronal adhesion and neurite outgrowth. Nature 389:852-856.

Condic ML, Snow DM, Letourneau PC (1999) Embryonic neurons adapt to the inhibitory proteoglycan aggrecan by increasing integrin expression. J Neurosci 19:10036-10043.

Cregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J (2014) Functional regeneration beyond the glial scar. Exp Neurol 253:197-207.

Dalseg AM, Guastello H, Bock E (1993) Molecular biology of cadherins in the nervous system. Mol Neurobiol 7:207-228.

Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J (1997) Regeneration of adult axons in white matter tracts of the central nervous system. Nature 390:680-683.

del Zoppo G, Miller R (2006) Integrin-matrix interactions in the cerebral microvasculature. Arterioscler Thromb Vasc Biol 26:1966-1975.

DePaul MA, Lin CY, Silver J, Lee YS (2015) Peripheral nerve transplantation combined with acidic fibroblast growth factor and chondroitinase regeneration and improves sensory function in complete spinal cord transection in adult mice. PLoS One 10:e0139355.

Desgriselle JS, Chersh DA (2010) Integrins in cancer: biological implications and therapeutically opportunities. Nat Rev Cancer 10:9-22.

Doye JP, Dougherty JD, Heiman M, Schmidt EF, Stevens TR, Ma G, Bupp S, Shesko P, Shah RD, Doughtry ML, Gong S, Greengard P, Heintz N (2005) Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135:749-762.

Eddleston M, Mucke L (1993) Molecular profile of reactive astrocytes—implications for their role in neurologic disease. Neuroscience 54:15-36.

Ellis V, Voronov S, Davis K (1991) Plasmagomin activation by receptor bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752-12758.

Fasen K, Elger CE, Lie AA (2003) Distribution of alpha and beta integrin subunits in the rat hippocampus after pilocarpine-induced neuronal cell loss, axonal reorganization and reactive astrocytosis. Acta Neuropathol 106:319-322.

Fawcett JW (2006) Overcoming inhibition in the damaged spinal cord. J Neurol Sci 241:313-320.

Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV (1999) Mammalian homologues of the Drosophila slit protein are ligands of the heparan sulfate proteoglycan glypican-1 in brain. J Biol Chem 274:17885-17892.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.

Fawcett JW, Abercrombie AW, Spartaliani N, Cerione RA (2006) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator gene. J Biol Chem 281:3725-3736.
Nathan and Li / Neural Regeneration Research. 2017;12(12):1964-1970.

Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, Kuchlerlapati R, Raine CS (1996) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. NeuroReport 7:607-615.

Lindholm D, Castrén E, Kiefer R, Zafra F, Thoenen H (1992) Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 117:995-1000.

Liu K, Tedeschi A, Park KK, He Z (2011) Neuronal intrinsic mechanisms of axon regeneration. Ann Rev Neurosci 34:131-152.

Margolis RK, Margolis RU (1994) Nerve tissue proteoglycans. EXS 70:145-167.

McCull MC, Gregg RG, Behringer RR, Brenner M, Delaney CL, Galbreath EL, Zhang CL, Pearce RA, Chiu SY, Messing A (1996) Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci U S A 93:6361-6366.

McKeon RI, Schreiber RC, Rudge JS, Silver J (1991) Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci 11:3398-3411.

McKillop WM, Dragan M, Schreiber RR, Brown A (2013) Conditional Sox9 ablation reduces chondroitin sulfate proteoglycan levels and improves motor function following spinal cord injury. Glia 61:164-177.

Merrill R, Chen X, Ming GL, Spatz P, Doppo GJ (2008) Responses of endothelial cell and astrocyte matrix-integrin receptors to ischemia mimicking those observed in the neurovascular unit. Stroke 39:191-197.

Molofsky AV, Krenclik R, Ullian EM, Tsai HH, Deneen B, Richardson WD, Barres BA, Rowitch DH (2012) Astrocytes and disease: a neurodevelopmental perspective. Genes Dev 26:891-907.

Nedergaard M, Ransom B, Goldman SA (2003) New roles for astrocytes: refining the functional architecture of the brain. Trends Neurosci 26:523-530.

Ohtake Y, Li S (2015) Molecular mechanisms of scar-forming axon growth inhibition. Brain Res 1619:22-35.

Okada S, Nakamura M, Kato H, Miyao T, Shimazaki T, Ishii K, Yamane J, Yamanaka Y, Iwamoto Y, Toyama Y, Okano H (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12:829-835.

Pégion F, Étienne-Manneville S (2012) N-cadherin expression level as a critical indicator of invasion in non-neoplastic tumours. Cell Adh Migr 6:327-343.

Pekny M, Nilsson M (2005) Astrocyte activation and reactive glia. Glia 39:427-434.

Pekny M, Leiven P, Pekna M, Eliasson C, Berthold CH, Westmark B, Betsholtz C (1995) Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J 14:1590-1598.

Pekny M, Johansson CB, Eliasson C, Stakeberg J, Wallen A, Perllmann T, Daniél U, Betsholtz C, Berthold CH, Frisen J (1999) Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol 145:503-514.

Pellerin L, Bouzier-Sore AK, Aubert A, Serres S, Merle M, Costalat R, Magistretti PJ (2007) Activity-dependent regulation of energy metabolism by astrocytes. Trends Biochem Sci 25:388-391.

Previtai SC, Archelos JJ, Hartung HP (1997) Modulation of the expression of N-cadherin in primary astrocyte cultures. J Neurochem 105:272-278.

Rutishauser U, Landmesser L (1996) Polyaspartic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Trends Neurosci 19:422-427.

Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, Akassoglou K (2010) Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 30:5843-5854.

Schwartz MA, Shattil SJ (2000) Signaling networks linking integrins and rho family GTPases. Trends Biochem Sci 25:388-391.

Seifert G, Schilling K, Steinhauser C (2006) Astrocyte dysfunction in neurologic disorders: a molecular perspective. Nat Rev Neurosci 7:194-206.

Sharma K, Selzer ME, Li S (2012) Scar-mediated inhibition and CSPG receptors in the CNS. Exp Neurol 237:370-378.

Shintani Y, Wheelock MJ, Johnson KR (2006a) Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol Biol Cell 17:2963-2975.

Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR (2006b) Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 66:11745-11753.

Silver J, Müller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146-156.

Silver J, Schwartz M (1995) Glial cell types, lineages, and response to injury in rat and fish: implications for regeneration. Glia 13:157-165.

Silver GM, Strum C (2005) Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52:209-218.

Sofroniew MV (2009) Molecular dissection of reactive astroglia and glial scar formation. Trends Neurosci 32:638-647.

Sofroniew MV (2014) Astroglia. Cold Spring Harb Perspect Biol 7:2002042.

Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:35-58.

Stoll CT, Lommers P, Sock E, Wachowiak MS, Schell B, Wegner M (2003) The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev 17:1677-1689.

Sundberg C, Ivarsson M, Gerdin B, Rubin K (1996) Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 74:452-466.

Susarla BT, Laing ED, Yu P, Katagiri Y, Yeller CM, Symes AJ (2011) Smad proteins differentially regulate transforming growth factor-beta-mediated induction of chondroitin sulfate proteoglycans. J Neurochem 119:868-878.

Takeuchi M (2007) The cadherin superfamily in neuronal connections and interactions. Nat Rev Neurosci 8:11-20.

Takeuchi K, Yoshioka N, Higa Onaga S, Watanabe Y, Miyata S, Wada Y, Kudo C, Okada M, Okho K, Oda K, Sato T, Yokoyama M, Matsushita N, Nakamura M, Okano H, Sakurai K, Kawano H, Kitagawa H, Igarashi M (2013) Chondromodulin sulphate N-acetylgalactosaminytransferase-1 inhibits recovery from neural injury. Nat Commun 4:2740.

Tomaselli KJ, Neugebauer KM, Bixby JL, Lelien J, Reichardt LF (1988) N-cadherin and integrins: two receptor systems that mediate neuronal process outgrowth on astrocyte surfaces. Neuron 1:33-43.

Tower DB, Young OM (1973) The activities of butyrylcholinesterase and carboxylesterase in the nervous system of the vertebrates from mouse to whale. J Neurochem 11:3398-3411.

Tran MD, Wanner IB, Neary JT (2008) Purinergic receptor signaling regulates N-cadherin expression in primary astrocyte cultures. J Neurochem 103:272-286.

Vázquez-Chona F, Geisert EE, Jr. (1999) N-cadherin at the glial scar in the rat. Brain Res 838:45-50.

Vaugah JE, Pease DC (1967) Electron microscopy of classically stained astrocytes. J Comp Neurol 131:143-154.

Wilhelmus U, Bushong EA, Price DL, Smarr BL, Phung V, Terada M, Ellman MH, Pekny M (2006) Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc Natl Acad Sci U S A 103:17513-17518.

Wu DY, Schneider GE, Silver J, Poston M, Jhaveri S (1998) A role for tectal midline glia in the unilateral containment of retinoocular axons. J Neurosci 18:3834-3835.

Yokota K, Kobayakawa K, Kubota K, Miyawaki A, Okano H, Ohkawa Y, Iwamoto Y, Okada S (2013) Neurotrophin-4 and/or Progenitor Cells Promote Functional Recovery through Synapse Reorganization with Spared Host Neurons after Spinal Cord Injury. Stem Cell Reports 5:264-277.

Yonezawa T, Hattori S, Inagaki J, Kurosaki M, Takigawa T, Hirohata S, Miyoshi T, Ninomiya Y (2010) Type IV collagen induces expression of transforming growth factor beta-1 that is mediated by integrin alpha1beta1 in astrocytes. Glia 58:755-767.